Cardiac Toxicity of ErbB2-Targeted Therapies: What Do We Know?

Ainger, 1971, Daunomycin: a cardiotoxic agent, J Natl Med Assoc, 63, 261 Lefrak, 1973, A clinicopathologic analysis of adriamycin cardiotoxicity, Cancer, 32, 302, 10.1002/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2 Von Hoff, 1979, Risk factors for doxorubicininduced congestive heart failure, Ann Intern Med, 91, 710, 10.7326/0003-4819-91-5-710 Alexander, 1979, Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography, N Engl J Med, 300, 278, 10.1056/NEJM197902083000603 Billingham, 1978, Anthracycline cardiomyopathy monitored by morphologic changes, Cancer Treat Rep, 62, 865 Mackay, 1994, Assessment of anthracycline cardiomyopathy by endomyocardial biopsy, Ultrastruct Pathol, 18, 203, 10.3109/01913129409016291 Ewer, 2005, Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity, J Clin Oncol, 23, 2900, 10.1200/JCO.2005.05.827 Ewer, 2004, A mathematical model for doxorubicin cardiotoxicity: added evidence for the concept of sequential stress, Proc Am Soc Clin Oncol, 23, 148 Ewer, 2007, Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer, Clin Breast Cancer, 7, 600, 10.3816/CBC.2007.n.017 Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, 783, 10.1056/NEJM200103153441101 Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106 Slamon, 1989, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, 244, 707, 10.1126/science.2470152 Chien, 2006, Herceptin and the heart—a molecular modifier of cardiac failure, N Engl J Med, 354, 789, 10.1056/NEJMp058315 Crone, 2002, ErbB2 is essential in the prevention of dilated cardiomyopathy, Nat Med, 8, 459, 10.1038/nm0502-459 Ewer, 2005, Reversibility of trastuzumab- related cardiotoxicity: new insights based on clinical course and response to medical treatment, J Clin Oncol, 23, 7820, 10.1200/JCO.2005.13.300 Seidman, 2002, Cardiac dysfunction in the trastuzumab clinical trials experience, J Clin Oncol, 20, 1215, 10.1200/JCO.20.5.1215 Lemmens, 2004, Neuregulin-1 induces a negative inotropic effect in cardiac muscle: role of nitric oxide synthase, Circulation, 109, 324, 10.1161/01.CIR.0000114521.88547.5E Sawyer, 2002, Modulation of anthracycline- induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1β and anti-erbB2: potential mechanism for trastuzumabinduced cardiotoxicity, Circulation, 105, 1551, 10.1161/01.CIR.0000013839.41224.1C Perez, 2006, Results of an analysis of cardiac function in 2,812 patients treated with lapatinib, J Clin Oncol, 24, 23s Negro, 2004, Essential roles of Her2/erbB2 in cardiac development and function, Recent Prog Horm Res, 59, 1, 10.1210/rp.59.1.1 2006 Perez, 2005, Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial, J Clin Oncol, 23, 17s Romond EH, Perez EA, Bryant J, et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer. Combined analysis of NSABP-B31/NCCTG-N9831. Presented at: 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, FL. Slamon Piccart-Gebhart, 2005, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer, N Engl J Med, 353, 1659, 10.1056/NEJMoa052306 Romond, 2005, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, N Engl J Med, 353, 1673, 10.1056/NEJMoa052122 Bria E, Cuppone F, Fornier M, et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat; July 19, 2007 (Epub ahead of print). Perez, 2007, Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer, J Clin Oncol, 25, 6s Rastogi, 2007, Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)→ paclitaxel (T) vs. AC→T with trastuzumab (H), J Clin Oncol, 25, 964s Smith, 2007, 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial, Lancet, 369, 29, 10.1016/S0140-6736(07)60028-2 Slamon Perez, 2008, Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial, J Clin Oncol, 26, 1231, 10.1200/JCO.2007.13.5467 Geyer, 2006, Update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)→ paclitaxel (T) vs. AC→T with trastuzumab (H), J Clin Oncol, 24, 23s Suter, 2007, Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial, J Clin Oncol, 25, 3859, 10.1200/JCO.2006.09.1611 Geyer, 2006, Lapatinib plus capecitabine for HER2-positive advanced breast cancer [published correction appears in N Engl J Med 2007; 356:1487], N Engl J Med, 355, 2733, 10.1056/NEJMoa064320 Perez, 2006, Cardiac safety experience in 3558 patients treated with lapatinib, Annals Oncol, 17, ix70 Storniolo, 2007, Cardiac safety in patients (pts) with metastatic breast cancer (MBC) treated with lapatinib (L) and trastuzumab (TRA), J Clin Oncol, 25, 6s Kutteh, 2007, A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER2-positive breast cancer, J Clin Oncol, 25, 22s